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Abstract
Obesity is associated with a worse breast cancer prognosis, while greater breast tumor
estrogen receptor beta (ERβ) expression is correlated with improved therapy response and
survival. The objective of this study was to determine the impact of obesity on breast cancer
cell ERβ expression, which is currently unknown. We utilized an in vitromodel of obesity in
which breast cancer cells were exposed to patient serum pooled by body mass index cate-
gory (obese (OB):30 kg/m2; normal weight (N): 18.5–24.9 kg/m2). Four human mammary
tumor cell lines representing the major breast cancer subtypes (SKBR3, MCF-7, ZR75,
MDA-MB-231) and mammary tumor cells from MMTV-neu mice were used. ERβ expres-
sion, assessed by qPCR and western blotting, was suppressed in the two HER2-overex-
pressing cell lines (SKBR3, MMTV-neu) following OB versus N sera exposure, but did not
vary in the other cell lines. Expression of Bcl-2 and cyclin D1, two genes negatively regu-
lated by ERβ, was elevated in SKBR3 cells following exposure to OB versus N sera, but this
difference was eliminated when the ERβ gene was silenced with siRNA. Herceptin, a HER2
antagonist, and siRNA to HER2 were used to evaluate the role of HER2 in sera-induced
ERβmodulation. SKBR3 cell treatment with OB sera plus Herceptin increased ERβ expres-
sion three-fold. Similar results were obtained when HER2 expression was silenced with
siRNA. OB sera also promoted greater SKBR3 cell viability and growth, but this variance
was not present when ERβ was silenced or the cells were modified to overexpress ERβ.
Based on this data, we conclude that obesity-associated systemic factors suppress ERβ
expression in breast cancer cells via a HER2-mediated pathway, leading to greater cell via-
bility and growth. Elucidation of the mechanism(s) mediating this effect could provide impor-
tant insights into how ERβ expression is regulated as well as how obesity promotes a more
aggressive disease.
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Introduction
The National Cancer Institute estimates that one in eight women born in the United States
today will develop breast cancer at some point in their lives [1]. A multitude of factors have
been shown to affect an individual’s risk of developing breast cancer as well as her breast cancer
prognosis, and one modifiable lifestyle factor that impacts both disease risk and outcome is
obesity. A number of studies have demonstrated that obesity negatively affects breast cancer
prognosis for both pre- and postmenopausal women. Obese patients do not respond as well to
chemotherapy treatment [2–4], and an elevated body mass index (BMI) has been associated
with increased metastatic recurrence and decreased disease-free interval and overall survival
across breast cancer subtypes [5–9]. Our understanding of the mechanisms mediating this link
between obesity and poor breast cancer outcome remains incomplete, hindering efforts to
develop new chemotherapeutic regimens that may improve prognosis in the obese patient
population.
In addition to lifestyle factors like obesity, breast cancer outcome is significantly affected
by the non-modifiable characteristics of a given tumor, including tumor expression of estro-
gen receptor alpha (ERα), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2). The presence or absence of these three protein receptors are the primary
defining characteristics of the four major breast cancer subtypes, listed here in increasing
order of aggressiveness: luminal A (ERα+, PR+/-, HER2-), luminal B (ERα+, PR+/-, HER2
+/-), HER2-overexpressing (ERα+/-, PR+/-, HER2+), and triple-negative (ERα-, PR-, HER2-
) [10]. While ERα expression is generally considered to be a positive prognostic marker [11],
ERα activity does promote breast cancer cell proliferation, survival, and motility [12–13].
This is in contrast with the activity of estrogen receptor beta (ERβ), a second estrogen recep-
tor that was first identified in 1995. Multiple studies have demonstrated that higher tumor
expression of ERβ is correlated with an improved prognosis in all breast cancer subtypes [14–
20], suggesting that ERβmay act as a tumor suppressor. These findings are supported by in
vitromodels that show ectopic expression of ERβ in ERα positive breast cancer cells results in
decreased growth, motility, and invasion [21–25]. In addition, tumor formation and angio-
genesis in mouse xenografts was reduced with ERβ overexpression [23,26]. Finally, the pro-
tective effect of ERβ expression is further evidenced by its decreased expression in breast
cancer cells, particularly in higher versus lower-grade tumors [22,26–30]. In normal mam-
mary tissue, ERβ is the predominant ER, but its expression is inhibited via promoter hyper-
methylation in breast cancer cells [31–32]. However, approximately 76% of breast tumors still
express detectable levels of ERβ, leading a number of researchers to explore its potential as a
therapeutic target [33].
While many studies have been devoted to the examination of whether increased ERβ
activity can improve breast cancer outcome, relatively little attention has been paid to
expanding our understanding of the factors affecting ERβ expression. In addition, the effects
of obesity on breast cancer cell ERβ expression remain completely unknown, though a
reduced ERβ expression may be a potentially targetable mechanism by which obesity pro-
motes a worse breast cancer prognosis. In the current study, we utilized an in vitromodel
of obesity to investigate how obesity-associated systemic factors affect ERβ expression in
multiple cell lines representing the four major breast cancer subtypes. We demonstrate that
exposure to obesity-associated systemic factors reduces ERβ expression in two HER2-overex-
pressing breast cancer cell lines, one human and murine-derived. We further establish that
this effect occurs via a HER2-mediated signaling pathway and leads to increased cell viability
and growth.
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Materials and Methods
Serum samples
Serum was collected from 25 non-fasting postmenopausal breast cancer patients. BMI was cal-
culated, and serum was pooled according to the BMI category of the patient (normal weight (N:
18.5–24.9 kg/m2), n = 5; obese (OB:30.0 kg/m2), n = 20). The characteristics of the serum
donors, including serum concentrations of various cytokines, adipokines, and growth factors as
well as potential confounding conditions and medications, have been previously described [34].
Cell lines
SKBR3, MCF-7, ZR75, and MDA-MB-231 human breast cancer cell lines (ATCC Numbers
HTB-30, HTB-22, CRL-1500, and HTB-26, respectively) were maintained in IMEM (GIBCO
Life Technologies, Grand Island, USA) supplemented with 10% fetal bovine serum (FBS).
Mammary tumor cells isolated fromMMTV-neu transgenic mice were cultured in DMEM
(GIBCO Life Technologies) plus 10% FBS. The MMTV-neu cell line was derived from a single
spontaneous mammary tumor excised from a female MMTV-neu transgenic mouse following
euthanasia. MMTV-neu mice (JAX stock #002376, FVB/N-Tg(MMTVneu)202Mul/J) were
purchased from Jackson Laboratory (Bar Harbor, ME). Mice were singly housed and fed a high
carbohydrate, low fat diet (#D12450B, Research Diets, Inc., New Brunswick, NJ) ad libitum.
The tumor was dissected, mechanically dissociated into small pieces, and plated in 10 mL of
media in 100 mm plates, grown at 37°C in 5% CO2 in DMEMmedia, 10% FBS, 1% penicillin/
streptomycin and 1% Fungizone (all media components from HyClone, Waltham, MA) over-
night. After 24 hours, the supernatant was removed and floating cells and mammary fat pad
pieces were pelleted using centrifugation at 850 RPM for 5 minutes. The resulting cell pellet
was resuspended in 10 mL of complete media in a new 100 mm plate. The cell line, denoted as
MMTV-neu E18-9A-42, was cultured for a minimum of 4 weeks prior to use.
Ethics Statement
The serum samples described above were collected at the Cancer Therapy and Research Center
of University of Texas Health Science Center at San Antonio (UTHSCSA) under a bio-reposi-
tory collection protocol approved by UTHSCSA’s Institutional Review Board (HSC20070684H).
The collection and use of these biological samples was conducted in accordance with the Decla-
ration of Helsinki and good clinical practice. Written informed consent was obtained prior to
participation, and all samples and data were de-identified prior to release to maintain patient
confidentiality.
The isolation of the MMTV-neu murine mammary tumor cell line described above was car-
ried out in strict accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of the University of Texas at Austin (AUP-
2012-00066). Tumor removal was performed following euthanasia via CO2 inhalation and cer-
vical dislocation, and all efforts were made to minimize suffering.
Reagents
The primary antibody for ERβ was purchased from abcam (Cambridge, MA, USA). The β-
actin primary antibody was produced by Cell Signaling (Beverly, MA, USA). Herceptin is
manufactured by Genentech Inc. (San Francisco, USA). ON-TARGETplus siRNA to ESR2,
ON-TARGETplus SMARTpool siRNA to ERBB2 (a pool of four siRNA), and a negative con-
trol siRNA were purchased from GE Healthcare Dharmacon Inc. (Pittsburgh, PA, USA). All
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siRNAs were transiently transfected into SKBR3 cells using FuGENE HD transfection reagent
(Roche, Switzerland) per manufacturer's instructions. The pAcGFP1-C1-ER beta plasmid, a
GFP-tagged ESR2 overexpression plasmid, was a kind gift from Dr. Ratna Vadlamudi
(UTHSCSA). This plasmid was transfected into SKBR3 cells using FuGENE HD, and G418
(Life Technologies) was used to stably select transfected cells. Clones were selected and the two
with the highest ESR2 expression (SKBR3-ERB#3 and SKBR3-ERB#5), as determined by
RT-PCR, maintained in IMEM plus 10% FBS and 500 ug/ml G418. Dr. Carla Van Den Berg
(University of Texas at Austin) generously provided the pGFP vector, which was also stably
transfected into SKBR3 cells (SKBR3-GFP) using FuGENE HD.
Quantitative RT-PCR
ESR2mRNA levels in all cell lines were quantified following an 18-hour serum-starvation
period and a one-hour exposure to a 2% concentration of pooled OB or N patient sera in
serum-free media (SFM). BCL2 and CCND1mRNA levels in SKBR3 cells were quantified after
an 18-hour serum-starvation period and a 24-hour exposure to 2% pooled OB or N sera in
SFM. To determine whether sera-induced differences in the expression of these genes was
attributable to differences in ESR2 expression, ESR2 was silenced using siRNA (10 nM). To
assess the role of HER2 receptor signaling in the observed effects of the sera on ESR2 expres-
sion, SKBR3 cells were pre-treated for one hour with Herceptin (1.0 ug/ml) prior to sera expo-
sure. ERBB2 expression was also silenced using siRNA (25 nM). To examine whether the obese
patient sera modulates ESR2 expression at the transcriptional level or post-transcription, two
stable ESR2-overexpressing SKBR3 cell lines were utilized. Total RNA was isolated using TRI-
zol reagent (Invitrogen) and reverse transcribed with Promega’s ImProm II Reverse Transcrip-
tion System. The primer sequences are as follows: human ESR2: forward, 5’-ATGGAGTC
TGGTCGTGTGAAGG-3’; reverse, 5’-TAACACTTCCGAAGTCGGAGG-3’; mouse Esr2: for-
ward, 5’-GACTGTAGAACGGTGTGGTCATCAA-3’; reverse, 5’-CTGTGAGGTAGGAATGC
GAA AC-3’; human ERBB2: forward, 5’-GGAGCCGCGAGCACCGAAGT-3’; reverse, 5’-
CGGCCAGGGCATAGT TGTCC-3’. ESR2 primers were designed to amplify the transcript
encoding the full-length ERβ1 isoform. The manufacturer’s recommended cycling conditions
for the QuantiFast SYBR Green PCR kit (Qiagen, Valencia, USA) were used for these genes.
For BCL2 and CCND1mRNA quantification, Taqman1 Gene Expression Assays were used
(Applied Biosystems, Waltham, MA). Data shown represents the average of at least three inde-
pendent experiments.
Western Blot Analysis
ERβ protein levels in all cells lines were quantified following an 18-hour serum-starvation
period and a two-hour exposure to a 2% concentration of pooled OB or N patient sera in SFM.
Radioimmunoprecipitation assay (RIPA) buffer was used for protein extraction. Protein con-
tent of the lysates was measured using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA,
USA). Images were acquired using a Bio-Rad VersaDoc Imaging System and quantified using
Bio-Rad Quantity One software. Relative ERβ protein levels were calculated by first standardiz-
ing ERβ protein levels to β-actin, then dividing the standardized protein level for each condi-
tion by that of cells grown in the OB sera. Quantification data shown represents the average of
at least three independent experiments.
MTT Assay
SKBR3 cells were seeded in IMEM supplemented with 10% FBS in 10 cm plates and grown to a
confluence of at least 50%. Plates were then transfected with the ESR2 or negative control
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siRNA and incubated for 24 hours. In addition, one plate received no transfection. These cells
were then seeded at a density of 5x103 in 96 well plates. After a 24-hour incubation, the cells
were continuously exposed to 2% OB or N patient sera in SFM for seven days. On day four of
the treatment period, the wells were aspirated and washed with PBS, and the media was replen-
ished with the same concentration of sera. Cell viability was then measured as described previ-
ously [34]. SKBR3, SKBR3-GFP, SKBR3-ERB#3 and SKBR3-ERB#5 cells were seeded in IMEM
supplemented with 10% FBS at a density of 5x103 in 96 well plates. After 24 hours, they were
exposed to 2% OB or N patient sera in SFM for seven days as described above, and cell viability
was measured. Relative cell viability was calculated by dividing each absorbance value by the
absorbance for SKBR3 cells grown in N patient sera after being transfected with negative con-
trol siRNA (for the ESR2 siRNA experiment) or receiving no transfection (for the ESR2-overex-
pressing clones experiment). Data shown represents the average of at least three independent
experiments.
Colony Formation Assay
SKBR3 cells were seeded in IMEM supplemented with 10% FBS in 10 cm plates, grown to at
least 50% confluence, and then transfected or left without transfection as described above for
the MTT assay. These cells were then seeded at a density of 1x103 in six well plates. After 24
hours of growth in the 10% FBS media, the cells were then continuously exposed to 2% OB or
N patient sera in SFM for ten days. On day five of the treatment period, the wells were aspirated
and washed with PBS, and the media was replenished with the same concentration of sera.
SKBR3, SKBR3-GFP, SKBR3-ERB#3 and SKBR3-ERB#5 cells were seeded in IMEM supple-
mented with 10% FBS at a density of 1x103 in six well plates and after 24 hours exposed to 2%
OB or N patient sera in SFM for 10 days as described above. On day ten, the colonies were
fixed and stained with 1% crystal violet in 70% acetic acid for 30 minutes and then counted.
The relative number of colonies, a reflection of cell growth, was calculated by dividing each col-
ony count by the count for SKBR3 cells grown in N patient sera after being transfected with
negative control siRNA (for the ESR2 siRNA experiment) or receiving no transfection (for the
ESR2-overexpressing clones experiment) and multiplying by 100. Data shown represents the
average of at least three independent experiments.
Statistical Analyses
Differences between cells exposed to two different experimental conditions were measured
using Student’s t test, with asterisks indicating significant differences between the two condi-
tions in figures. Two-way ANOVA was used to analyze the data from experiments with more
than one independent variable, with different letters indicating significant differences in fig-
ures. In this system, “a” indicates that a condition is significantly different from another condi-
tion marked with a “b”, and a third condition marked with a “c” is significantly different from
both “a” and “b”. A condition marked with a double letter, such as “a,b”, indicates that it is sta-
tistically equivalent to both “a” and “b”, but is significantly different from “c”. A p value of
<0.05 was considered significant.
Results
Obesity-associated systemic factors inhibit ERβ expression in HER2/
neu-overexpressing breast cancer cell lines
We began by measuring ESR2mRNA and ERβ protein levels in response to patient sera in a
panel of human breast cancer cell lines representing the four major breast cancer subtypes.
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Time course experiments were conducted to determine optimal sera exposure time (data not
shown). ESR2 expression in the HER2-overexpressing SKBR3 cell line was 41% (± 7.3%)
greater (p<0.01) following a one-hour incubation in N versus OB patient sera (Fig 1A). ERβ
protein levels in SKBR3 cells exposed to N patient sera for two hours were also 45% (± 14%)
greater (p<0.05) in comparison to OB sera (Fig 1B). In contrast, there was no significant differ-
ence in ESR2mRNA and ERβ protein levels in MCF-7, ZR75, or MDA-MB-231 cells after
exposure to N versus OB patient sera (Fig 1C and 1D). These three cell lines are representative
of the luminal A, luminal B, and triple negative breast cancer subtypes, respectively, and all
express low levels of HER2. Consequently, we measured the impact of patient sera exposure
on mammary tumor cells isolated fromMMTV-neu mice, which also overexpress HER2,
and found that ESR2mRNA levels were 67% (± 11.4%) higher (p<0.01) and ERβ protein
levels were 44% (± 3.0%) greater (p<1x10-5) in cells exposed to N versus OB patient sera (Fig
1A and 1B).
Suppression of ERβ expression by obesity-associated systemic factors
modulates Bcl-2 and Cyclin D1 expression
To determine whether the observed changes in SKBR3 cell ERβ expression are of sufficient
magnitude to affect the expression of downstream ERβ target genes, we next measured the
impact of patient sera exposure on two of these genes: the anti-apoptotic BCL2 gene and the
pro-proliferative CCND1 gene, which encodes cyclin D1. An ESR2 knock-down condition was
included in these experiments to verify that any changes in BCL2 and CCND1 expression were
due to upstream differences in ESR2 expression. Transient transfection with siRNA to ESR2
resulted in a 70% (± 2.7%) reduction in SKBR3 cell ESR2mRNA levels (p<0.01), while trans-
fection with negative control siRNA did not significantly affect ESR2 expression (Fig 2A). Fol-
lowing a 24-hour exposure to N patient sera, BCL2 and CCND1 expression levels in non-
transfected SKBR3 cells were 48% (± 3.1%) and 79% (± 3.0%), respectively, of the levels seen
with OB sera exposure (p<0.05 for BCL2) (Fig 2B and 2C). Similar, though non-significant,
differences between the N and OB sera conditions in the expression of these genes were found
in SKBR3 cells transfected with the negative control siRNA. Silencing ESR2 significantly
increased the expression of both genes in comparison to non-transfected and negative control
siRNA cells exposed to N patient sera (p<0.001 for BCL2, p<0.05 for CCND1), consistent with
the effects of OB sera exposure on these genes. The variance between the N and OB sera condi-
tions in BCL2 and CCND1 expression was also eliminated by ESR2 knock-down, providing fur-
ther support for the hypothesis that the differences between the N and OB sera conditions seen
in the non-transfected and negative control siRNA cells are due to upstream differences in
ESR2 expression.
Obesity-associated systemic factors inhibit transcription of the ERβ
gene
After demonstrating that exposure to obesity-associated systemic factors inhibits SKBR3 cell
ERβ expression and modulates ERβ target genes, we next examined whether these effects occur
via the regulation of ESR2 transcription or through a post-transcriptional mechanism. We
compared ESR2 expression in SKBR3 cells stably transfected with a GFP-tagged ESR2 overex-
pression plasmid (SKBR3-ERB#3 and #5 clones) or an empty pGFP vector (SKBR3-GFP) to
the parental SKBR3 cell line following a one-hour exposure to N or OB patient sera. As seen
previously, ESR2mRNA levels were significantly higher in the parental SKBR3 cells exposed to
N versus OB sera, and a similar difference was seen in the SKBR3-GFP cells (p<0.05). In con-
trast, there was no difference in ESR2 expression between the N and OB conditions in the
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SKBR3-ERB#3 and #5 clones, which did have significantly higher ESR2 levels in comparison to
the parental SKBR3 cells (p<0.05) (Fig 3A). These results indicate that obesity-associated sys-
temic factors suppress ESR2 expression at the transcriptional level, as the OB patient sera had
no inhibitory effect on ESR2mRNA levels when the gene was overexpressed using a constitu-
tively active promoter.
Inhibition of HER2 signaling attenuates obesity-induced suppression of
SKBR3 cell ERβ expression
Given that a difference in ERβ expression following N versus OB patient sera exposure was
only observed in HER2-overexpressing cell lines, we next examined whether the effects of the
OB sera may be mediated by HER2 signaling by utilizing the HER2-targeting monoclonal anti-
body Herceptin. SKBR3 ESR2mRNA levels increased by 2.79-fold (± 0.27) with Herceptin
treatment prior to and during OB sera exposure in comparison to OB sera alone (p<0.0001).
In contrast, HER2 inhibition in SKBR3 cells exposed to N patient sera resulted in a non-signifi-
cant increase in ESR2mRNA levels over N sera alone. Consequently, ESR2mRNA levels were
significantly higher (p<0.05) in OB versus N sera-exposed SKBR3 cells when HER2 signaling
was suppressed with Herceptin (Fig 3B). These results strongly suggest that the HER2 receptor
plays a role in mediating the effects of OB patient sera on breast cancer cell ESR2 expression.
HER2 receptor silencing reverses obesity-induced suppression of
SKBR3 cell ERβ expression
To further assess the role of HER2 signaling in the OB patient sera-induced suppression of
SKBR3 cell ERβ expression, we next silenced the gene for the HER2 receptor (ERBB2) using
Fig 1. ERβ expression is suppressed by obesity-associated systemic factors in HER2-overexpressing breast cancer cells. (A) ESR2mRNA levels,
measured by quantitative RT-PCR, in SKBR3 breast cancer cells and mammary carcinoma cells isolated fromMMTV-neu mice following a 1-hour exposure
to normal weight (N) or obese (OB) patient sera. (B) ERβ protein levels, measured by western blotting, in SKBR3 and MMTV-neu cells following a 2-hour
exposure to N or OB patient sera. (C) ESR2mRNA levels, measured by quantitative RT-PCR, in MCF-7, ZR75, and MDA-MB-231 breast cancer cells
following a 1-hour exposure to N or OB patient sera. (D) ERβ protein levels, measured by western blotting, in MCF-7, ZR75, and MDA-MB-231 cells following
a 2-hour exposure to N or OB patient sera. Data shown represents the average of at least three independent experiments. *, p<0.05; **, p<0.01 relative to
OB
doi:10.1371/journal.pone.0145452.g001
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siRNA. Transfection of SKBR3 cells with ERBB2-targeting siRNA resulted in an approximately
50% decrease (p<0.05) in ERBB2mRNA levels, while transfection with a negative control
siRNA sequence did not significantly alter ERBB2 expression (Fig 3C). ERBB2 silencing prior
to OB sera exposure led to a 2.32-fold (± 0.27) increase (p<0.05) in SKBR3 cell ESR2mRNA
levels in comparison to non-transfected SKBR3 cells. However, in SKBR3 cells exposed to N
sera, there was no significant change in ESR2 expression with ERBB2 silencing (Fig 3D). This
data provides additional evidence in support of the hypothesis that obesity-associated systemic
factors suppress breast cancer cell ERβ expression via a HER2-mediated signaling pathway.
Breast cancer cell viability and growth are increased by the obesity-
associated inhibition of ERβ expression
To determine the clinical relevance of these findings, we assessed whether obesity-induced ERβ
suppression promotes two in vitromeasures of breast cancer progression: cell viability and
Fig 2. Obesity-associated systemic factors modulate expression of the ERβ target genesBCL2 andCCND1. (A) ESR2mRNA and ERβ protein levels,
measured by quantitative RT-PCR and western blotting respectively, in SKBR3 cells without transfection (No siR) or following transfection with a negative
control siRNA (Neg siR) or siRNA to ESR2 (ESR2 siR). (B) BCL2mRNA levels, measured by quantitative RT-PCR, in SKBR3 cells transfected with No siR,
Neg siR, or ESR2 siR and exposed to 2% normal weight (N) or obese (OB) patient sera for 24 hours. (C) CCND1mRNA levels, measured by quantitative
RT-PCR, in SKBR3 cells and transfected with No siR, Neg siR, or ESR2 siR and exposed to 2% N or OB patient sera for 24 hours. Data shown represents
the average of at least three independent experiments. Different letters indicate statistically significant differences, p<0.05.
doi:10.1371/journal.pone.0145452.g002
Obesity Inhibits Estrogen Receptor Beta Expression
PLOS ONE | DOI:10.1371/journal.pone.0145452 December 28, 2015 8 / 15
growth. Following a 7-day exposure to OB sera, the viability of non-transfected SKBR3 cells
was 49% (± 14.0%) higher in comparison to cells cultured in the N sera (p<0.05), with a similar
difference seen in SKBR3 cells transfected with negative control siRNA (p<0.05). However,
silencing of ESR2 expression with siRNA significantly increased the viability of SKBR3 cells
exposed to N patient sera, eliminating the difference between the N and OB sera conditions
(Fig 4A). This suggests that the difference in SKBR3 cell viability that follows incubation in the
N versus OB sera is mediated by differences in ESR2 expression. Exposure to OB versus N sera
also enhanced SKBR3 cell growth, as evidenced by a 2.13-fold (± 0.10) increase in the relative
number of colonies formed in non-transfected SKBR3 cells (p<0.01) and a similar elevation
in negative control siRNA-transfected SKBR3 cells cultured in OB versus N patient sera
(p<0.05). ESR2 knock-down with siRNA increased colony formation in SKBR3 cells exposed
to N patient sera (p<0.001), again eliminating the difference between the N and OB sera
Fig 3. Obesity-associated systemic factors inhibit ESR2 gene transcription via HER2 signaling. (A) ESR2mRNA levels in parental SKBR3 cells and
SKBR3 cells stably transfected with an empty pGFP vector (SKBR3-GFP) or a GFP-tagged ESR2 overexpression plasmid (SKBR3-ERB#3 and #5).
Quantitative RT-PCRwas used to assess ESR2mRNA levels following exposure to normal weight (N) or obese (OB) patient sera for 1 hour. (B) ESR2mRNA
levels, measured by quantitative RT-PCR, in SKBR3 cells exposed to N or OB patient sera for 1 hour +/- 1.0 ug/ml Herceptin (H). (C) ERBB2 expression,
measured by quantitative RT-PCR, in SKBR3 cells without transfection (No siR) or following transfection with negative control siRNA (Neg siR) or siRNA to
ERBB2 (ERBB2 siR). (D) ESR2 expression, measured by quantitative RT-PCR, after a 1-hour exposure to OB or N patient sera, in SKBR3 cells transfected
with No siR, Neg siR, or ERBB2 siR. Data shown represents the average of at least three independent experiments. Different letters indicate statistically
significant differences, p<0.05.
doi:10.1371/journal.pone.0145452.g003
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conditions (Fig 4B). These results indicate that the growth-enhancing effects of the OB patient
sera are likely attributable to the sera’s inhibition of ESR2 expression.
We further explored the intersection between obesity-associated systemic factors, SKBR3
cell ESR2 expression, and cell viability and growth by assessing the impact of the patient sera
on these in vitromeasures of breast cancer progression in our ESR2-overexpressing SKBR3
clones, which express equal levels of ESR2 following exposure to OB and N patient sera (Fig
3A). After a 7-day incubation in OB sera, parental SKBR3 cell viability was 50% (± 4.0%)
greater in comparison to cells cultured in the N sera (p<0.05), consistent with the above
results. A similar difference was seen in SKBR3-GFP cells grown in these conditions, though it
did not reach statistical significance. This variation between OB and N was not seen in the
SKBR3-ERB#3 and #5 clones, though, and overexpression of ESR2 significantly reduced the
viability of cells exposed to OB sera when compared to parental SKBR3 and SKBR3-GFP cells
cultured in OB sera (p<0.05; Fig 4C). The relative number of colonies formed by the parental
SKBR3 cells was 82% (± 6.4%) higher after 10 days of growth in OB versus N sera (p<0.05). A
Fig 4. Breast cancer cell viability and growth are increased by the obesity-associated inhibition of ESR2 expression. (A) Cell viability, measured by
MTT assay, in SKBR3 cells without transfection (No siR) or with transfection of a negative control siRNA (Neg siR) or siRNA to ESR2 (ESR2 siR) and
following exposure to normal weight (N) or obese (OB) patient sera for 7 days. (B) Following 10 days of exposure to N or OB patient sera, colony formation
was assessed in No siR, Neg siR, and ESR2 siR SKBR3 cells. (C) Viability of parental SKBR3 cells and SKBR3 cells stably transfected with an empty pGFP
vector (SKBR3-GFP) or a GFP-tagged ESR2 overexpression plasmid (SKBR3-ERB#3 and #5) was measured by MTT assay after the cells were cultured in
N or OB patient sera for 7 days. (B) Following 10 days of exposure to N or OB patient sera, colony formation was assessed in parental SKBR3, SKBR3-GFP,
and SKBR3-ERB#3 and #5 cell lines. Data shown represents the average of at least three independent experiments. Different letters indicate statistically
significant differences, p<0.05.
doi:10.1371/journal.pone.0145452.g004
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greater number of colonies was also formed in SKBR3-GFP cells grown in OB versus N sera
(p<0.05). Overexpression of ESR2 drastically reduced the SKBR3 cells’ ability to form colonies
(p<0.05) and eliminated the ability of the OB sera to stimulate significantly greater cell growth
in comparison to N (Fig 4D). These findings provide further support for the hypothesis that
the OB sera-induced increases in SKBR3 cell viability and colony formation are mediated by
the sera’s inhibition of ESR2 expression, as these effects are not seen when the differences in
ESR2 expression are eliminated.
Discussion
While the literature does not indicate that obesity increases HER2+ breast cancer risk [35],
studies have found that an elevated BMI is associated with a worse breast cancer outcome
across all subtypes after adjustment for HER2 status [9] and specifically in patients with HER2
+/ERα- tumors [36]. A reduction in ERβ expression may be one mechanism by which obesity
promotes the progression of one or more breast cancer subtypes. In the years following the dis-
covery of ERβ, researchers have devoted substantial resources to exploring the functions of this
second ER, with many focused on defining how ERβ activity impacts breast cancer prognosis.
The consensus among most investigators of this subject is that greater ERβ expression and
activity is associated with an improved outcome [14–20]. In contrast, few studies have exam-
ined the mechanisms by which ERβ expression is regulated. Here we have demonstrated that
exposure to obesity-associated systemic factors suppresses transcription of the gene for ERβ in
HER2-overexpressing breast cancer cells, and this effect is reversed by HER2 inhibition or
silencing. Human ERβ gene transcription is known to be controlled by at least two promoters,
0N and 0K, with transcripts from 0N predominating in both normal and transformed breast
epithelial cells [31,37]. Promoter 0N, cloned in 2000, has silencer elements in a region contain-
ing a putative AP-1 binding site [38]. Given that HER2 signaling is known to activate AP-1
[39], this binding site is a potential mechanistic link between elevated HER2 activity and a
reduction in ERβ expression.
However, it is still unclear how obesity-associated systemic factors might activate this
HER2-mediated ERβ-suppressing pathway. We have previously reported that the levels of
interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα), and leptin were significantly higher,
and adiponectin levels lower, in the obese patient serum samples utilized in this study, com-
pared to the normal weight patient samples. In addition, insulin levels were elevated three-fold
in the obese patients, but free insulin-like growth factor (IGF)-1 concentrations did not vary
between the obese and normal weight women [34]. Consequently, one possible mediator of the
obese patient sera’s effects on ERβ expression is the IGF-1 receptor (IGF1R), as both insulin
and IGF-1 can promote IGF1R activation [40–41]. Several studies have demonstrated cross-
talk between HER2 and IGF1R [42–44], suggesting that obesity-induced IGF1R signaling may
further enhance HER2 activity. IGF1R signaling may also independently impact ERβ expres-
sion, as silencing of this receptor in MCF-7 breast cancer cells has been shown to increase ERβ
levels [45]. Both the IL-6 and leptin receptors (IL-6R and ObR, respectively) also cross-talk
with HER2 and thereby enhance its signaling. In the presence of IL-6, HER2 forms a complex
with the gp130 subunit of the IL-6R, and this leads to MAPK pathway activation [46]. ObR
also physically interacts with HER2 following leptin treatment, stimulating HER2 tyrosine
phosphorylation [47]. These links suggest that obesity-associated circulating factors may be
suppressing ERβ expression in HER2+ breast cancer cells by further amplifying HER2 signal-
ing, resulting in AP-1 activation and the subsequent inhibition of ERβ gene transcription.
However, while the current study demonstrated that HER2 inhibition significantly increases
ERβ expression in cells exposed to obesity-associated circulating factors, supporting the
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conclusion that HER2 mediates the obesity-ERβ link, we also showed that HER2 inhibition
non-significantly increases ERβ expression in cells exposed to N sera. This finding may reflect
the fact that, like the OB sera, the N sera contains HER2-activating insulin, IL-6, and leptin,
but in lower amounts. Consequently, one or more of these factors may be present in sufficient
amounts to cause some suppression of ERβ expression by the N sera via stimulation of HER2
signaling, so that the inhibition of that signaling leads to a non-significant increase in ERβ
expression. We were also intrigued to find that ERβ expression in our ERβ over-expressing
SKBR3 cell clones did not change with exposure to OB versus N sera. Some difference between
the N and OB conditions in the clones’ ERβ expression was expected because endogenous ERβ
expression, which is impacted by OB sera exposure, is still present. The lack of a difference
may be due to a negative feedback loop that is triggered once ERβ expression exceeds a certain
level. Only endogenous ERβ expression would be affected by this inhibitory loop, not the con-
stitutively active promoter in the ERβ overexpression plasmid, leading to elevated levels of ERβ
expression in the clones that are unaffected by sera exposure.
Given that ERβ is generally considered to be a tumor suppressor correlated with a better
breast cancer prognosis [14–20], we also examined whether the obesity-induced suppression of
this protein was associated with changes in in vitromeasures of breast cancer progression.
Researchers have previously shown that ERβ expression and activity inhibits breast cancer cell
proliferation and growth in both in vitro and in vivomodels [21,23–24,26]. In agreement with
these findings, we demonstrated that the decreased SKBR3 cell ERβ expression that follows
obese patient sera exposure is associated with greater cell viability and growth. These effects can
be attributed to the obese patient sera-induced inhibition of ERβ transcription, as ERβ silencing
or overexpression prevented the sera’s enhancement of SKBR3 cell viability and growth. Conse-
quently, the suppression of ERβ expression may be a mechanism by which obesity promotes
breast cancer progression, particularly in patients with HER2-overepressing tumors.
In conclusion, the current study demonstrates that obesity-associated systemic factors suppress
ERβ expression in breast cancer cells that overexpress HER2, revealing a new potential mecha-
nism by which obesity promotes a more aggressive disease. While HER2 inhibition and silencing
were definitively shown to reverse this effect, the precise signaling pathway connecting obesity,
HER2, and ERβ expression remains unclear. Greater understanding of this pathway will enhance
our knowledge regarding the regulation of ERβ expression and may suggest new potential thera-
peutic targets for the obese patient population. The focus of our future studies will thus be elucida-
tion of the molecular mechanisms mediating this effect as well as determination of whether the
observed obesity-induced inhibition of ERβ levels affects breast cancer progression in vivo.
Supporting Information
S1 Text. ARRIVE Checklist.
(PDF)
Author Contributions
Conceived and designed the experiments: LB AB RT SH LD. Performed the experiments: LB
MW ER. Analyzed the data: LB MW ER. Contributed reagents/materials/analysis tools: AB RT
SH LD. Wrote the paper: LB MW ER LD.
References
1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (eds). SEER Cancer Sta-
tistics Review, 1975–2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_
2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
Obesity Inhibits Estrogen Receptor Beta Expression
PLOS ONE | DOI:10.1371/journal.pone.0145452 December 28, 2015 12 / 15
2. Litton JK, Gonzalez-Angulo AM,Warneke CL, Buzdar AU, Kau SW, Bondy M, et al. Relationship
between obesity and pathologic response to neoadjuvant chemotherapy among women with operable
breast cancer. J Clin Oncol. 2008; 26:4072–7. doi: 10.1200/JCO.2007.14.4527 PMID: 18757321
3. Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KD, Shao ZM. Obesity or overweight is associated with worse
pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS
One. 2012; 7:e41380. doi: 10.1371/journal.pone.0041380 PMID: 22848477
4. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between
body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.
Oncologist. 2012; 17:1240–5. doi: 10.1634/theoncologist.2012-0169 PMID: 22903527
5. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influ-
ences duration of disease-free survival. Ann Intern Med. 1992; 116:26–32. PMID: 1727092
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer
in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625–38. PMID: 12711737
7. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent progno-
sis factor in woman breast cancer? Breast Cancer Res Treat. 2008; 111:329–42. PMID: 17939036
8. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic
review and meta-analysis. Breast Cancer Res Treat. 2010; 123:627–35. doi: 10.1007/s10549-010-
0990-0 PMID: 20571870
9. Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable
breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological sub-
types: a pooled analysis. Breast Cancer Res. 2013; 15:R105. doi: 10.1186/bcr3572 PMID: 24192331
10. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implica-
tions. Nature Clin Pract Oncol. 2007; 4:516–25.
11. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res.
2004; 6:109–18. PMID: 15084231
12. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003; 5:239–47.
PMID: 12927032
13. Cortez V, Mann M, Brann DW, Vadlamudi RK. Extranuclear signaling by estrogen: role in breast cancer
progression and metastasis. Minerva Ginecol. 2010; 62:573–83. PMID: 21079578
14. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, et al. Estrogen receptor beta expression
in invasive breast cancer. Hum Pathol. 2001; 32:113–8. PMID: 11172304
15. Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, et al. Clinical significance of the
expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Che-
mother Pharmacol. 2003; 52 Suppl 1:S34–8. PMID: 12819932
16. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, et al. Estrogen
receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in
breast cancer. Clin Cancer Res. 2004; 10:5769–76. PMID: 15355905
17. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta pro-
tein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004; 10:7490–9.
PMID: 15569979
18. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, et al. Inverse relationship
between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer.
2004; 91:1687–93. PMID: 15477868
19. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, et al. The
favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast can-
cer. J Clin Pathol. 2004; 57:523–8. PMID: 15113861
20. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen recep-
tor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol.
2008; 26:3727–34. doi: 10.1200/JCO.2007.14.2968 PMID: 18669459
21. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of
breast cancer cells. Endocrinology. 2001; 142:4120–30. PMID: 11517191
22. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estro-
gen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001; 61:2537–
41. PMID: 11289127
23. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta
inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.
Cancer Res. 2004; 64:423–8. PMID: 14729654
Obesity Inhibits Estrogen Receptor Beta Expression
PLOS ONE | DOI:10.1371/journal.pone.0145452 December 28, 2015 13 / 15
24. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits
17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA.
2004; 101:1566–71. PMID: 14745018
25. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene net-
works regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006; 147:4831–42.
PMID: 16809442
26. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor beta inhibits
angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006; 66:11207–13. PMID:
17145865
27. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast
tumors. J Clin Endocrinol Metab. 1997; 82:2371–4. PMID: 9215322
28. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger
RNA expression during human breast tumorigenesis. Cancer Res. 1998; 58:3197–201. PMID:
9699641
29. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Tsukamoto F, Noguchi S. Quantitative analysis of estrogen
receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase
chain reaction. Cancer. 2000; 89:1732–8. PMID: 11042568
30. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha
and beta differ in normal human breast and breast carcinomas. J Pathol. 2002; 198:450–7. PMID:
12434414
31. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, et al. Expression of estrogen
receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.
Oncogene. 2003; 22:7600–6. PMID: 14576822
32. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, et al. Methylation of estrogen
receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an
early indication marker in premalignant lesions. Endocr Relat Cancer. 2005; 12:903–16. PMID:
16322330
33. Murphy L, Cherlet T, Lewis A, Banu Y, Watson P. New insights into estrogen receptor function in
human breast cancer. Ann Med. 2003; 35:614–31. PMID: 14708971
34. Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA. Obesity enhances
nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro
measures of breast cancer progression. Breast Cancer Res. 2013; 15:R59. PMID: 23880059
35. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast
cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consor-
tium studies. J Natl Cancer Inst. 2011; 103:250–63. doi: 10.1093/jnci/djq526 PMID: 21191117
36. Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, et al. Obesity increases
the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor
receptor 2-positive breast cancer patients. Eur J Cancer. 2013; 49:3588–97. doi: 10.1016/j.ejca.2013.
07.016 PMID: 23953055
37. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl
Recept Signal. 2008; 6:e003. doi: 10.1621/nrs.06003 PMID: 18301783
38. Li LC, Yeh CC, Nojima D, Dahiya R. Cloning and characterization of human estrogen receptor beta pro-
moter. Biochem Biophys Res Commun. 2000; 275:682–9. PMID: 10964723
39. Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, et al. Oncogenic Neu/
ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation
blocks Neu-mediated cellular transformation. J Biol Chem. 1996; 271:7992–8. PMID: 8626480
40. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human
obesity. Metabolism. 1995; 44:37–44. PMID: 7476310
41. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, et al. Effect of obesity on total and free insulin-
like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insu-
lin, and growth hormone. Int J Obes Relat Metab Disord. 1997; 21:355–9. PMID: 9152736
42. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors
causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit.
2002; 8:BR521–6. PMID: 12503030
43. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epi-
dermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast can-
cer cells. Cancer Res. 2005; 65:11118–28. PMID: 16322262
Obesity Inhibits Estrogen Receptor Beta Expression
PLOS ONE | DOI:10.1371/journal.pone.0145452 December 28, 2015 14 / 15
44. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2:
dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res. 2008; 68:1538–
45. doi: 10.1158/0008-5472.CAN-07-5935 PMID: 18316619
45. Mendoza RA, Enriquez MI, Mejia SM, Moody EE, Thordarson G. Interactions between IGF-I, estrogen
receptor-alpha (ERalpha), and ERbeta in regulating growth/apoptosis of MCF-7 human breast cancer
cells. J Endocrinol. 2011; 208:1–9. doi: 10.1677/JOE-10-0235 PMID: 20974640
46. Qiu Y, Ravi L, Kung HJ. Requirement of ERBB2 for signalling by interleukin-6 in prostate carcinoma
cells. Nature. 1998; 393:83–5. PMID: 9590694
47. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, et al. Leptin/HER2 crosstalk in breast
cancer: in vitro study and preliminary in vivo analysis. BMCCancer. 2008; 8:305. doi: 10.1186/1471-
2407-8-305 PMID: 18945363
Obesity Inhibits Estrogen Receptor Beta Expression
PLOS ONE | DOI:10.1371/journal.pone.0145452 December 28, 2015 15 / 15
